Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors

As prospective clinical trials continue to accrue data, the researchers indicated that this data may help clinicians in decision-making regarding adjuvant systemic therapy for patients with small HR-positive, ERBB2-positive breast cancers.

Source: CancerNetwork - April 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news